Relay Therapeutics: Patel proposes $1.81M share sale
The shares are identified as restricted stock units acquired from Relay Therapeutics on February 10, 2025, and two prior 10b5-1 sales are listed.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. (RLAY) reports a proposed sale for Sanjiv Patel’s account of 96,401 common shares, with an aggregate market value of $1,806,554.74. The approximate sale date is October 7, 2026, and Morgan Stanley Smith Barney LLC is listed as broker. The shares are identified as restricted stock units acquired from the issuer on February 10, 2025. Two prior sales labeled 10b5-1 Sales are listed for the preceding three months: 48,199 shares for $913,096.32 on September 8, 2026, and 48,199 shares for $980,049.55 on August 17, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Units financial
10b5-1 Sales financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.